Chinese Journal of Dermatology ›› 2024, Vol. 57 ›› Issue (4): 374-378.doi: 10.35541/cjd.20210248
• Reviews • Previous Articles Next Articles
Yan Rufan1, Liao Jieyue2, Guo Ziyu2, Yao Nan2, Zhou Wenyu2, Luo Shuaihantian2, Zhang Guiying2, Zhao Ming2
Received:2021-03-24
Revised:2021-12-22
Online:2024-04-15
Published:2024-04-07
Contact:
Luo Shuaihantian; Zhang Guiying
E-mail:lsht5309@csu.edu.cn; lindazgy@ csu.edu.cn
Supported by:Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus[J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.doi:10.35541/cjd.20210248
| ［1］ | Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities［J］. Immunol Res, 2018,66（2）:255⁃270. doi: 10.1007/s12026⁃018⁃8986⁃7. |
| ［2］ | Sinha AA, Sajda T. The evolving story of autoantibodies in pemphigus vulgaris: development of the "super compensation hypothesis"［J］. Front Med （Lausanne）, 2018,5:218. doi: 10. 3389/fmed.2018.00218. |
| ［3］ | Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management［J］. Clin Exp Dermatol, 2019,44（7）:740⁃746. doi: 10.1111/ced.14041. |
| ［4］ | Hashimoto T, Amagai M, Watanabe K, et al. A case of pemphigus vulgaris showing reactivity with pemphigus antigens （Dsg1 and Dsg3） and desmocollins［J］. J Invest Dermatol, 1995,104（4）:541⁃544. doi: 10.1111/1523⁃1747.ep12606050. |
| ［5］ | Lotti R, Atene CG, Marconi A, et al. Development of a desmocollin⁃3 active mouse model recapitulating human atypical pemphigus［J］. Front Immunol, 2019,10:1387. doi: 10. 3389/fimmu.2019.01387. |
| ［6］ | Grando SA. Cholinergic control of epidermal cohesion［J］. Exp Dermatol, 2006,15（4）:265⁃282. doi: 10.1111/j.0906⁃6705.2006. 00410.x. |
| ［7］ | Lakshmi M, Jaisankar TJ, Rajappa M, et al. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus［J］. J Am Acad Dermatol, 2017,76（5）:895⁃902. doi: 10.1016/j.jaad.2016.11.039. |
| ［8］ | Chernyavsky A, Chen Y, Wang PH, et al. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis［J］. Int Immunopharmacol, 2015,29（1）:76⁃80. doi: 10.1016/j.intimp. 2015.04.046. |
| ［9］ | Vincent A. Unravelling the pathogenesis of myasthenia gravis［J］. Nat Rev Immunol, 2002,2（10）:797⁃804. doi: 10.1038/nri916. |
| ［10］ | Rakocević⁃Stojanović V, Rakocević I, Perić S, et al. Intravenous immunoglobulin therapy in two patients with myasthenia gravis and pemphigus vulgaris［J］. Acta Myol, 2009,28（3）:101⁃102. |
| ［11］ | Bhatia SM, Streilein RD, Hall RP. Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab［J］. PLoS One, 2020,15（6）:e0233957. doi: 10.1371/journal.pone.0233957. |
| ［12］ | Zhang F, Yan X, Jiang D, et al. Eight novel mutations of ATP2C1 identified in 17 Chinese families with Hailey⁃Hailey disease［J］. Dermatology, 2007,215（4）:277⁃283. doi: 10.1159/000107620. |
| ［13］ | Malan M, Xuejingzi W, Si J, et al. Hailey⁃Hailey disease: the role of azathioprine an immunomodulator［J］. Pan Afr Med J, 2019,32:65. doi: 10.11604/pamj.2019.32.65.17877. |
| ［14］ | Kalantari⁃Dehaghi M, Anhalt GJ, Camilleri MJ, et al. Pemphigus vulgaris autoantibody profiling by proteomic technique［J］. PLoS One, 2013,8（3）:e57587. doi: 10.1371/journal.pone.0057587. |
| ［15］ | Kugelmann D, Rötzer V, Walter E, et al. Role of Src and cortactin in pemphigus skin blistering［J］. Front Immunol, 2019,10:626. doi: 10.3389/fimmu.2019.00626. |
| ［16］ | Walter E, Vielmuth F, Rotkopf L, et al. Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus［J］. Sci Rep, 2017,7（1）:3579. doi: 10.1038/s41598⁃017⁃03697⁃7. |
| ［17］ | Petzl⁃Erler ML. Beyond the HLA polymorphism: a complex pattern of genetic susceptibility to pemphigus［J］. Genet Mol Biol, 2020,43（3）:e20190369. doi: 10.1590/1678⁃4685⁃gmb⁃2019⁃0369. |
| ［18］ | Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum （EDF） in cooperation with the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2015,29（3）:405⁃414. doi: 10.1111/jdv.12772. |
| ［19］ | 夏登梅, 闫薇, 徐飞, 等. HLA⁃DRB1等位基因与四川汉族人寻常型天疱疮的相关性研究［J］. 中华皮肤科杂志, 2017,50（8）:589⁃591. doi: 10.3760/cma.j.issn.0412⁃4030.2017.08.010. |
| ［20］ | Zhang SY, Zhou XY, Zhou XL, et al. Subtype⁃specific inherited predisposition to pemphigus in the Chinese population［J］. Br J Dermatol, 2019,180（4）:828⁃835. doi: 10.1111/bjd.17191. |
| ［21］ | Mahmoudi H, Ebrahimi E, Daneshpazhooh M, et al. Single⁃nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine［J］. Int J Immunogenet, 2020,47（1）:41⁃49. doi: 10.1111/iji. 12451. |
| ［22］ | Fang SY, Li CL, Liu XS, et al. Correlation between polymorphisms of the NR3C1 gene and glucocorticoid effectiveness in patients with pemphigus vulgaris［J］. Sci Rep, 2017,7（1）:11890. doi: 10.1038/s41598⁃017⁃12255⁃0. |
| ［23］ | Egu DT, Walter E, Spindler V, et al. Inhibition of p38MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis［J］. Br J Dermatol, 2017,177（6）:1612⁃1618. doi: 10.1111/bjd.15721. |
| ［24］ | Vielmuth F, Walter E, Fuchs M, et al. Keratins regulate p38MAPK⁃dependent desmoglein binding properties in pemphigus［J］. Front Immunol, 2018,9:528. doi: 10.3389/fimmu.2018.00528. |
| ［25］ | Chatzikyriakidou A, Voulgari PV, Georgiou I, et al. The role of microRNA⁃146a （miR⁃146a） and its target IL⁃1R⁃associated kinase （IRAK1） in psoriatic arthritis susceptibility［J］. Scand J Immunol, 2010,71（5）:382⁃385. doi: 10.1111/j.1365⁃3083.2010. 02381.x. |
| ［26］ | Zhai Y, Xu K, Leng RX, et al. Association of interleukin⁃1 receptor⁃associated kinase （IRAK1） gene polymorphisms （rs3027898, rs1059702） with systemic lupus erythematosus in a Chinese Han population［J］. Inflamm Res, 2013,62（6）:555⁃560. doi: 10.1007/s00011⁃013⁃0607⁃2. |
| ［27］ | Chatzikyriakidou A, Kyriakou A, Meltzanidou P, et al. Association of NFKB1 ⁃94ATTG ins/del polymorphism （rs28362491） with pemphigus vulgaris［J］. Exp Dermatol, 2019,28（8）:972⁃975. doi: 10.1111/exd.13957. |
| ［28］ | Fetter T, Niebel D, Braegelmann C, et al. Skin⁃associated B cells in the pathogenesis of cutaneous autoimmune diseases⁃implications for therapeutic approaches［J］. Cells, 2020,9（12）:2627. doi: 10.3390/cells9122627. |
| ［29］ | Mélet J, Mulleman D, Goupille P, et al. Rituximab⁃induced T cell depletion in patients with rheumatoid arthritis: association with clinical response［J］. Arthritis Rheum, 2013,65（11）:2783⁃2790. doi: 10.1002/art.38107. |
| ［30］ | Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus （Ritux 3）: a prospective, multicentre, parallel⁃group, open⁃label randomised trial［J］. Lancet, 2017,389（10083）:2031⁃2040. doi: 10.1016/S0140⁃6736（17）30070⁃3. |
| ［31］ | Karatzi C, Stefanidou M, Islamidou E, et al. Beware of anal fissures: pemphigus vulgaris of the anal canal［J］. Ann Gastroenterol, 2019,32（2）:205⁃207. doi: 10.20524/aog.2018.0340. |
| ［32］ | Gupta J, Raval RC, Shah AN, et al. Low⁃dose rituximab as an adjuvant therapy in pemphigus［J］. Indian J Dermatol Venereol Leprol, 2017,83（3）:317⁃325. doi: 10.4103/ijdvl.IJDVL_1078_14. |
| ［33］ | Kridin K, Kowalski EH, Kneiber D, et al. From bench to bedside: evolving therapeutic targets in autoimmune blistering disease［J］. J Eur Acad Dermatol Venereol, 2019,33（12）:2239⁃2252. doi: 10.1111/jdv.15816. |
| ［34］ | Pharmaceuticals N. Efficacy and safety of ofatumumab in treatment of pemphigus vulgaris［DB/OL］. （2019⁃06⁃06）［2021⁃04⁃02］. https://clinicaltrials.gov/ct2/show/NCT01920477. |
| ［35］ | Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B⁃cell⁃activating factor associated with increased pathogen⁃specific IgG but not autoantibodies in pemphigus vulgaris［J］. J Invest Dermatol, 2009,129（9）:2202⁃2210. doi: 10.1038/jid.2009.27. |
| ［36］ | Kowalczyk⁃Quintas C, Chevalley D, Willen L, et al. Inhibition of membrane⁃bound BAFF by the anti⁃BAFF antibody belimumab［J］. Front Immunol, 2018,9:2698. doi: 10.3389/fimmu.2018. 02698. |
| ［37］ | Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin⁃1alpha and tumor necrosis factor⁃alpha mRNA in pemphigus vulgaris: interleukin⁃1alpha and tumor necrosis factor⁃alpha are involved in acantholysis［J］. J Invest Dermatol, 2000,114（1）:71⁃77. doi: 10.1046/j.1523⁃1747.2000. 00835.x. |
| ［38］ | Kaya Erdogan H, Yuksel Canakci N, Acer E, et al. Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: a case report［J］. Dermatol Ther, 2020,33（4）:e13801. doi: 10.1111/dth.13801. |
| ［39］ | Andrés TS, Alexandro B, de Oca⁃Sánchez Griselda M, et al. Etanercept plus methotrexate: an effective combination therapy for recalcitrant pemphigus vulgaris［J］. J Res Med Sci, 2015,20（3）:317. |
| ［40］ | Didona D, Fania L, Di Zenzo G, et al. Erythromycin⁃induced pemphigus foliaceus successfully treated with etanercept［J］. Dermatol Ther, 2020,33（6）:e14201. doi: 10.1111/dth.14201. |
| ［41］ | Siddiqi HF, Staser KW, Nambudiri VE. Research techniques made simple: CAR T⁃cell therapy［J］. J Invest Dermatol, 2018,138（12）:2501⁃2504.e1. doi: 10.1016/j.jid.2018.09.002. |
| ［42］ | Prasad V. Immunotherapy: tisagenlecleucel ⁃ the first approved CAR⁃T⁃cell therapy: implications for payers and policy makers［J］. Nat Rev Clin Oncol, 2018,15（1）:11⁃12. doi: 10.1038/nrclinonc.2017.156. |
| ［43］ | Clark RA. Slamming the brakes on lupus with CAR T cells［J］. Sci Immunol, 2019,4（34）:eaax3916. doi: 10.1126/sciimmunol.aax3916. |
| ［44］ | McHugh J. CAR T cells drive out B cells in SLE［J］. Nat Rev Rheumatol, 2019,15（5）:249. doi: 10.1038/s41584⁃019⁃0214⁃x. |
| ［45］ | Bio C. Open⁃label study to determine the maximum tolerated dose of DSG3⁃CAART in mucosal⁃dominant PV patients （mPV）［DB/OL］. （2020⁃01⁃26）［2021⁃04⁃02］. https://clinicaltrials.gov/ct2/show/NCT04422912. |
| [1] | Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429. |
| [2] | Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 0(4): 20220278-e20220278. |
| [3] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
| [4] | Ju Qiang, Li Jiaqi. Acne vulgaris revisited: from pathogenesis to treatment strategies [J]. Chinese Journal of Dermatology, 2024, 57(4): 289-294. |
| [5] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
| [6] | Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378. |
| [7] | Liu Tingwei, Meng Xiaoqi, Gu Duoduo, Pan Ruoxin, Zhang Yue, Xu Yang. Advances in the pathogenesis of rosacea [J]. Chinese Journal of Dermatology, 2024, 57(2): 186-190. |
| [8] | China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108. |
| [9] | Guo Lei, Cao Chunyan, Fang Xiaoya, Feng Suying. Analysis of current status and risk factors of multidrug-resistant bacteria wound infections in patients with autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2024, 57(2): 155-160. |
| [10] | Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of disease progression and influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 0(2): 20230167-e20230167. |
| [11] | Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723. |
| [12] | Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705. |
| [13] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
| [14] | Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524. |
| [15] | Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511. |
|
